Mineralys Therapeutics, Inc. (MLYS) Earnings Call Transcripts
Mineralys Therapeutics, Inc.'s Latest Earnings Call - June 9, 2026
In Q2 2026, Mineralys Therapeutics focused on the upcoming launch of Lorundrostat, with the NDA submitted and a PDUFA date set for later this year. The company reported a strategic acquisition of IP rights from Tanabe for $200 million upfront and $100 million in future milestones, which management claims will be accretive. No specific revenue or earnings figures were disclosed, but the company raised $150 million in equity and secured a $500 million debt facility to fund operations. Management expressed confidence in the potential market impact of Lorundrostat, particularly in the hypertension market.
Reported metrics
| Metric | Value |
|---|---|
| Royalty Buyback Cost | $200 million upfront, $100 million in milestones (neutral) |
| Equity Raise | $150 million (neutral) |
| Debt Facility | $500 million (neutral) |
| Hypertension Market Size | 20 million patients (positive) |
Guidance from management
Management expects to begin label negotiations with the FDA in Q4 2026 and is preparing for a launch contingent on PDUFA approval.
What management said
Yes. No. We're very excited about 2026 and the opportunity in front of us. As we noted, the NDA for Lorundrostat was submitted late last year. The PDUFA date was declared in March of this year that PDUFA is interactions with the FDA standard course, we continue to feel very positive about the opportunity, the approval we're using this year to continue to prepare for a successful launch of Lorundrostat, have built out...
Absolutely. So we had the opportunity to buy back the royalties from Tanabe for $200 million upfront and $100 million in future potential commercial milestones. The future milestones are based on certain thresholds, and we believe that they will be totally paid for by the savings in the royalty.
What analysts pressed on
Analysts questioned the financial impact of the Tanabe deal and the strategic rationale behind the large debt facility. Concerns were also raised about the competitive landscape and the ability to secure favorable market access.
Main topics on the call
- Lorundrostat NDA and PDUFA — Mineralys submitted the NDA for Lorundrostat, with the PDUFA date set for later this year. Management is preparing for a successful launch, targeting the hypertension market.
- Royalty Buyback from Tanabe — Mineralys acquired IP rights from Tanabe for $200 million upfront and $100 million in potential milestones, which management believes will be accretive due to savings on royalties.
- Financial Strategy and Fundraising — The company raised $150 million in equity and secured a $500 million debt facility to support its operations and upcoming product launch.
- Market Access and Pricing Strategy — Management is focusing on fourth-line entry for Lorundrostat, with a pricing strategy informed by recent competitor pricing. They aim for broad access without specialty tier pricing.
Read the full Mineralys Therapeutics, Inc. transcript (June 9, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc. (MLYS) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGS and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 22 calls on record spanning August 7, 2023 to June 9, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 22 Mineralys Therapeutics, Inc. earnings call transcripts on record, spanning August 7, 2023 to June 9, 2026. Based on this history, Mineralys Therapeutics, Inc. reports quarterly. The most recent call on file is dated June 9, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- MLYS
- Exchange
- NasdaqGS
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 22
- First call
- August 7, 2023
- Most recent
- June 9, 2026
- Reporting cadence
- quarterly